Virtual Library
Start Your Search
Di Lu
Author of
-
+
P2.03 - Biology (Not CME Accredited Session) (ID 952)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.03-31 - LncRNA RGMB-AS1 Affects Lung Adenocarcinoma Prognosis by Regulating Microtube Associated Genes: A Genome-Wide Analysis in Silicon (ID 12669)
16:45 - 18:00 | Author(s): Di Lu
- Abstract
Background
To analyze the co-expression network of long non-coding RNA RGMB-AS1 in lung adenocarcinoma (LUAD) and to investigate its impact on prognosis by mining the molecular mechanisms and prognostic signature in silicon.
a9ded1e5ce5d75814730bb4caaf49419 Method
We performed a co-expression analysis of RGMB-AS1 by integrating sixty thousand public Affymetrix microarrays data to reveal its associated signal pathways. QPCR and Western blot were performed to validate the significant genes. Furthermore, survival analysis of data in the Cancer Genome Atlas (TCGA) was applied to seek the prognostic value of RGMB-AS1 and its co-expressed genes.
4c3880bb027f159e801041b1021e88e8 Result
The most enriched signal pathways of RGMB-AS1 co-expressed genes were pathogenic Escherichia coli infection, gap junction and ubiquitin mediated proteolysis. Among the 30 validated genes, we found that a sixteen microtube-associated genes signature is an independent prognostic marker of OS of LUAD patients and demonstrates good performance for predicting 5-year OS.
8eea62084ca7e541d918e823422bd82e Conclusion
Our results suggest that RGMB-AS1 may serve as a novel prognosis indicator and therapeutic target for LUAD patients.
6f8b794f3246b0c1e1780bb4d4d5dc53
-
+
P2.12 - Small Cell Lung Cancer/NET (Not CME Accredited Session) (ID 961)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.12-08 - Network Meta-Analysis of Angiogenesis Inhibitors on Survival of Patients with Small Cell Lung Cancer (ID 12009)
16:45 - 18:00 | Author(s): Di Lu
- Abstract
Background
This network meta-analysis aimed at providing a comprehensive evaluation of the effects of angiogenic inhibitors on small cell lung cancer by using network meta-analysis.
a9ded1e5ce5d75814730bb4caaf49419 Method
The relative efficacy of angiogenesis inhibitors vandetanib (Van), bevacizumab (Bev), Rh-endostatin (End), sunitinib (Sun) and thalidomide (Tha) was evaluated by conducting a network meta-analysis of progression-free survival and overall survival.
4c3880bb027f159e801041b1021e88e8 Result
Nine phase II-III RCTs involving 1599 participants that investigated angiogenesis inhibitors on the treatment of SCLC were included. Sun and Bev achieved better PFS than Tha (Bev VS. Tha, HR=0.88, 95%CI: 0.79-0.98, Sun VS. Tha, HR=0.80, 95%CI: 0.65-1.00). Moreover, Sun and Bev were superior to placebo in terms of PFS (Bev VS. Placebo, HR=0.89, 95%CI: 0.81-0.97, Sun VS. Placebo, HR=0.81, 95% CI: 0.66-1.00). No significant difference of OS was found.
Figure 1 Networks of angiogenic inhibitors for the treatment of small-cell lung cancer.
8eea62084ca7e541d918e823422bd82e Conclusion
In this network meta-analysis, the effect of sunitinib and bevacizumab may be superior to that of thalidomide for small cell lung cancer.
6f8b794f3246b0c1e1780bb4d4d5dc53
